Lymphatic leukemia L 1210 cells were treated in vitro with various concentrations of Mafosfamide — a stabilized active derivative of cyclophosphamide (4-hydroxycyclophosphamide). L 1210 cells treated with Mafosfamide (L 1210-MAF cells) were used for vaccination of semisyngeneic CD2F1 mice against L 1210 leukemia. These cells do not grow in vivo but are viable in the test with trypan blue. L 1210-MAF cells, obtained by treatment of L 1210 cells two times with 50 μg/ml or 100 μg/ml of Mafosfamide, and injected into the mice induced resistance against L 1210 leukemia in these animals. L 1210 cells treated two times with higher concentration of Mafosfamide (200 μg/ml or 400 μg/ml) did not give this effect.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Alberts DS, Einspahr JG, Struck R, Bignami G, Young L, Surwit EA, Salmon SE: Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs 2:141–148, 1984
Turk JL, Parker D: Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 65:99–113, 1982
Diamantatein T, Klos M, Hahn H, Kaufmann SHE: Direct in vitro evidence for different susceptibilities to 4-hydroxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses. J Immunol 126:1717–1719, 1981
Douay L, Corin NC, Laporte J-P, Lopez M, Najman A, Duhamel G: ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 2:187–190, 1984
Kawalec M, Jakóbisiak M, Skórski T, Kawiak J: Immunogenicity of cyclophosphamide-treated leukemia cells. Folia Biol (Praha) 28:334–343, 1982
Skórski T, Kawalec M, Hoser G: Cyclophosphamide or ifosfamide treated L 1210 leukemia cells: immunogenicity, viability and metabolism. Folia Biol (Praha) 32:354–365, 1986
Lichtfield JT: A method for rapid graphic solution of time-percent effect curves. J Pharmacol Exp Ther 97:399–408, 1949
Lichtfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113, 1949
About this article
Cite this article
Skórski, T., Kawalec, M. New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z 7654) — immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug. Invest New Drugs 5, 167–169 (1987). https://doi.org/10.1007/BF00203542
- mafosfamide-treated L 1210 leukemia cells
- immune resistance
- CD2F1 mice